新型评分系统能否优于Mirels评分预测多发性骨髓瘤患者骨折风险?
研究基于单中心2003至2017年763例多发性骨髓瘤患者中174例长骨病变者,最终分析163例患者的163个病灶,开发了预测病理性骨折的新型评分系统,并与Mirels评分比较。新型评分系统敏感性更高(69% vs 38%,p<0.05),但特异性、阳性预测值、阴性预测值和ROC曲线下面积无差异。
要点
- 新型评分系统敏感性69%,高于Mirels评分的38%,更适合作为筛查工具。
- 特异性、阳性预测值、阴性预测值及AUC两者无统计学差异。
- 独立预测因素包括病灶面积、病灶潜伏期、疼痛和干骺端位置。
核心结论
- 新型评分系统在多发性骨髓瘤相关骨病中预测病理性骨折的敏感性优于Mirels系统,但特异性、PPV、NPV和AUC无差异。
研究设计与样本
- 单中心回顾性队列研究,2003至2017年763例多发性骨髓瘤患者中174例长骨病变,排除数据缺失及预防性固定者后分析163例患者的163个最大病灶。
主要发现
- 10%(16/163)患者发生骨折,4%(6/163)接受预防性固定被排除。
- 独立预测因素:病灶面积(log odds 0.17,p=0.03)、病灶潜伏期(log odds 0.25,p=0.03)、疼痛(RR 2.9,p=0.04)、干骺端位置(RR 3.2,p=0.003)。
- 新型评分敏感性69%(95%CI 61-76)vs Mirels 38%(95%CI 30-46),p<0.05。
- 特异性87%(95%CI 80-91)vs 87%(95%CI 81-92),PPV 37%(95%CI 29-45)vs 25%(95%CI 19-33),NPV 96%(95%CI 91-99)vs 92%(95%CI 87-96),AUC 0.85(95%CI 0.74-0.92)vs 0.67(95%CI 0.51-0.81),均p>0.05。
关键数值与推荐
- 新型评分系统基于病灶面积、病灶潜伏期、疼痛和干骺端位置构建,权重和截断值通过ROC曲线选择。
- 敏感性69% vs 38%(p<0.05),特异性87% vs 87%,PPV 37% vs 25%,NPV 96% vs 92%,AUC 0.85 vs 0.67(均p>0.05)。
临床怎么用
- 新型评分系统可作为筛查工具,帮助确定多发性骨髓瘤患者是否需要进一步影像学或骨科评估。
局限性
- 回顾性单中心研究,样本量有限,预防性固定患者被排除可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stratification of the fracture risk is an important treatment component for patients with multiple myeloma, which is associated with up to an 80% risk of pathologic fracture. The Mirels score, which is commonly used to estimate the fracture risk for patients with osseous lesions, was evaluated in a cohort in which fewer than 15% of lesions were caused by multiple myeloma. The behavior of multiple myeloma lesions often differs from that of lesions caused by metastatic disease, and accurate risk stratification is critical for effective care. To our knowledge, the Mirels score has not been validated specifically for multiple myeloma. QUESTIONS/PURPOSES: Our purpose was: (1) To develop a novel scoring system for the prediction of pathologic fracture in patients with long-bone lesions from multiple myeloma; and (2) to compare the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) area under curve (AUC) between the novel scoring system and the Mirels system. METHODS: Between 2003 and 2017, 763 patients at one center with the diagnosis of multiple myeloma were reviewed, of whom 174 presented with long-bone disease involvement. Of those, 5% (nine of 174) were missing data or radiographs at a minimum of 1 year and had not reached an endpoint (fracture or surgery) before that time and were therefore excluded. Many patients have more than one lesion; consequently, we used the largest lesion in each patient, resulting in 163 lesions in as many patients. Ten percent (16 of 163) of these patients eventually developed a fracture and 4% (six of 163) underwent prophylactic stabilization (excluded from analysis because of outcome uncertainty). During the study period, prophylactic stabilization was performed at the discretion of the orthopaedic oncologist. Fifty-one percent (83 of 163) of patients were female, and the mean (± SD) age was 60 ± 10 years at radiographic lesion identification. All lesions were characterized before determining whether the patient underwent pathologic fracture. We identified variables associated with pathologic fracture on univariate analysis. Variables independently significant on logistic regression analysis were used to generate scoring algorithms at varying weights and scoring cutoffs for comparison via ROC curves. We then selected a novel score based on ROC performance, and compared the sensitivity, specificity, PPV, and NPV of that scoring system to that of Mirels score. ROC AUCs were compared after bootstrapping 100,000 iterations. Alpha was set at 0.05. RESULTS: After controlling for potential confounders, such as age, sex, and duration of myeloma diagnosis, we found the following factors were independently associated with the occurrence of pathologic fracture: larger lesion size (area, cm2) (log odds 0.17; p = 0.03), longer lesion latency (years from diagnosis to lesion identification) (log odds 0.25; p = 0.03), presence of pain (relative risk [RR] 2.9; p = 0.04), and metaphyseal location (RR 3.2, compared with epiphyseal or diaphyseal; p = 0.003). These variables were used to formulate a novel scoring system. Compared with the Mirels system, the novel system was more sensitive (69% [95% CI 61 to 76] versus 38% [95% CI 30 to 46]; p < 0.05) but not different in terms of specificity (87% [95% CI 80 to 91] versus 87% [95% CI 81 to 92]; p > 0.05), PPV (37% [95% CI 29 to 45] versus 25% [95% CI 19 to 33]; p > 0.05), NPV (96% [95% CI 91 to 99] versus 92% [95% CI 87 to 96]; p > 0.05), or AUC (0.85 [95% CI 0.74 to 0.92] versus 0.67 [95% CI 0.51 to 0.81]; p > 0.05). CONCLUSION: The novel scoring system was found to be more sensitive than the Mirels system for predicting pathologic fracture in our retrospective cohort of patients with multiple myeloma-related bone disease. Specificity, PPV, NPV, and ROC AUC were not different with the numbers available. Thus, the novel scoring system may serve as a more effective screening tool to determine which patients with multiple myeloma would benefit from further radiologic or orthopaedic evaluation based on a skeletal survey. LEVEL OF EVIDENCE: Level III, diagnostic study.
引用
- Toci GR, Bressner JA, Morris CD, et al. Can a Novel Scoring System Improve on the Mirels Score in Predicting the Fracture Risk in Patients with Multiple Myeloma? Clin Orthop Relat Res. 2021. PMID: 32420721. doi:10.1097/CORR.0000000000001303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。